サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1342844

アトピー性皮膚炎治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Atopic Dermatitis Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 158 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
アトピー性皮膚炎治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 158 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アトピー性皮膚炎治療薬の世界需要は、2022年の96億3,000万米ドルから2030年には348億2,000万米ドルの市場規模に達すると推定され、調査期間2023～2030年のCAGRは17.43%です。

アトピー性皮膚炎（AD）は最も一般的な湿疹の一種で、世界人口の大部分が罹患しています。アトピー性皮膚炎は年齢に関係なく発症するが、新生児や小児に多く、年齢が上がるにつれて症状が改善します。

市場力学：

より多くの生物製剤や低分子の上市、ジェネリックの第一選択薬や第二選択薬の代替となる高価格薬、診断法の改善、ADの罹患率の増加といった主な要因が、アトピー性皮膚炎治療薬市場の成長を増大させると推定されます。さらに、アトピー性皮膚炎の治療法に関する認知度の向上も、過去数年間の市場の牽引役となっています。しかし、治療薬のコストが高いことが、市場の上昇を阻む要因の一つとなっています。とはいえ、より良い、より安価な治療を提供するために政府が行っている取り組みや、有利な償還政策は、市場に新たな機会を提供する可能性が高いです。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはアトピー性皮膚炎治療薬の世界市場における各セグメントを包括的に評価することもできます。アトピー性皮膚炎治療薬業界の成長と動向は、本調査に全体的なアプローチを提供します。

地域分析：

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるアトピー性皮膚炎治療薬市場の現在と将来の需要に焦点を当てた地域展望を取り上げます。さらに、本レポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 アトピー性皮膚炎治療薬の産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 アトピー性皮膚炎治療薬の世界市場分析：薬剤クラス別

  • 薬剤クラス別概要
  • 実績データと予測データ
  • 薬剤クラス別分析
  • 副腎皮質ステロイド薬
  • カルシニューリン阻害薬
  • PDE4阻害薬
  • 生物製剤
  • その他

第7章 アトピー性皮膚炎治療薬の世界市場分析：投与経路別

  • 投与経路別概要
  • 実績データと予測データ
  • 投与経路別分析
  • 外用薬
  • 注射剤
  • 経口

第8章 アトピー性皮膚炎治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 アトピー性皮膚炎治療薬企業の競合情勢

  • アトピー性皮膚炎治療薬の市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi
  • Galderma Laboratories L.P.
  • Eli Lilly and Company（Dermira）
  • Regeneron Pharmaceuticals Inc.
  • LEO Pharma Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Novartis AG
  • Incyte Corporation
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Calcineurin Inhibitors Market Sales by Geography (USD MN)
  • PDE4 Inhibitors Market Sales by Geography (USD MN)
  • Biologics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Route Of Administration (USD MN)
  • Topical Market Sales by Geography (USD MN)
  • Injectable Market Sales by Geography (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Global Atopic Dermatitis Drugs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Atopic Dermatitis Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Atopic Dermatitis Drugs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Calcineurin Inhibitors Market Sales by Geography (USD MN)
  • PDE4 Inhibitors Market Sales by Geography (USD MN)
  • Biologics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Topical Market Sales by Geography (USD MN)
  • Injectable Market Sales by Geography (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219522

The global demand for Atopic Dermatitis Drugs Market is presumed to reach the market size of nearly USD 34.82 BN by 2030 from USD 9.63 BN in 2022 with a CAGR of 17.43% under the study period 2023 - 2030.

Atopic dermatitis (AD) refers to the most common type of eczema, affecting a large percentage of the world's population. The condition can strike an individual at any age but is most common in newborns and children and becomes better as people get older.

MARKET DYNAMICS:

Major factors such as the launch of more biologics & small molecules, high-priced drugs substituting generic first-line and second-line therapeutics, improved diagnostics and growing incidence of AD is estimated to augment the atopic dermatitis drugs market growth. Furthermore, a rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. However, the high cost of therapeutics is one of the key roadblocks in the market's upward climb. Regardless, initiatives undertaken by governments to provide better and more affordable treatment and favourable reimbursement policies are likely to provide new opportunities in the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of atopic dermatitis drugs. The growth and trends of atopic dermatitis drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the atopic dermatitis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Corticosteroids
  • Calcineurin Inhibitors
  • Pde4 Inhibitors
  • Biologics
  • Others

By Route Of Administration

  • Topical
  • Injectable
  • Oral

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Atopic Dermatitis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the atopic dermatitis drugs market include Pfizer Inc., AbbVie Inc., Sanofi, Galderma Laboratories, L.P., Eli Lilly and Company (Dermira), Regeneron Pharmaceuticals Inc., LEO Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, Incyte Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ATOPIC DERMATITIS DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Corticosteroids Historic and Forecast Sales by Regions
  • 6.5 Calcineurin Inhibitors Historic and Forecast Sales by Regions
  • 6.6 PDE4 Inhibitors Historic and Forecast Sales by Regions
  • 6.7 Biologics Historic and Forecast Sales by Regions
  • 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1 Overview by Route Of Administration
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Route Of Administration
  • 7.4 Topical Historic and Forecast Sales by Regions
  • 7.5 Injectable Historic and Forecast Sales by Regions
  • 7.6 Oral Historic and Forecast Sales by Regions

8 . GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ATOPIC DERMATITIS DRUGS COMPANIES

  • 9.1. Atopic Dermatitis Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF ATOPIC DERMATITIS DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Pfizer Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Sanofi
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Galderma Laboratories L.P.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Eli Lilly and Company (Dermira)
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Regeneron Pharmaceuticals Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. LEO Pharma Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Otsuka Pharmaceutical Co. Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Novartis AG
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Incyte Corporation
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies